{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:19:06Z","timestamp":1773926346910,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.eururo.2018.01.012","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T20:51:31Z","timestamp":1517518291000},"page":"870-876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial"],"prefix":"10.1016","volume":"73","author":[{"given":"G\u00f6ran M.","family":"Ahlgren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Flodgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teuvo L.J.","family":"Tammela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pirkko","family":"Kellokumpu-Lehtinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Borre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Angelsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon Reidar","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asgerdur","family":"Sverrisdottir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eirikur","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Sengelov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2018.01.012_bib0100","unstructured":"NORDCAN. The NORDCAN project. http:\/\/www-dep.iarc.fr\/NORDCAN\/English\/frame.asp."},{"key":"10.1016\/j.eururo.2018.01.012_bib0105","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.eururo.2016.05.043","article-title":"Global incidence and mortality for prostate cancer: Analysis of temporal patterns and trends in 36 countries","volume":"70","author":"Wong","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.01.012_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2014.11.018","article-title":"Natural history of surgically treated high-risk prostate cancer","volume":"33","author":"Briganti","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2018.01.012_bib0115","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.juro.2015.12.074","article-title":"Risk stratification of pN+ prostate cancer after prostatectomy from a large single institutional series with long term follow-up","volume":"195","author":"Moschini","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2018.01.012_bib0120","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","article-title":"Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017","volume":"73","author":"Gillessen","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.01.012_bib0125","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2018.01.012_bib0130","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2018.01.012_bib0135","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa043681","article-title":"Adjuvant docetaxel for node-positive breast cancer","volume":"352","author":"Martin","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2018.01.012_bib0140","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0090-4295(97)00459-7","article-title":"Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument","volume":"50","author":"Esper","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2018.01.012_bib0145","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/jnci\/djg119","article-title":"Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative cancer: a randomized trial","volume":"95","author":"Castiglione-Gertsch","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2018.01.012_bib0150","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1158\/1078-0432.CCR-04-2140","article-title":"Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer","volume":"11","author":"Eigl","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2018.01.012_bib0155","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ijrobp.2015.05.024","article-title":"A phase 3 trial of 2 years of androgen suppression and radiation therapy with or without adjuvant chemotherapy for high-risk prostate cancer: Final results of radiation therapy oncology group phase 3 randomized trial NRG Oncology RTOG 9902","volume":"93","author":"Rosenthal","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl","key":"10.1016\/j.eururo.2018.01.012_bib0160","article-title":"A phase III protocol of androgen suppression (AS) and 3DCRT\/IMRT versus AS and 3DCRT\/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521)","volume":"33","author":"Sandler","year":"2015","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.eururo.2018.01.012_bib0165","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial","volume":"16","author":"Fizazi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2018.01.012_bib0170","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to \ufb01rst-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2018.01.012_bib0175","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data","volume":"17","author":"Vale","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2018.01.012_bib0180","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1002\/cncr.28270","article-title":"Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501)","volume":"119","author":"Schweizer","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2018.01.012_bib0185","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1464-410X.2011.10422.x","article-title":"The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up","volume":"109","author":"Antonarakis","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2018.01.012_bib0190","doi-asserted-by":"crossref","unstructured":"Dell\u2019Oglio P, Karnes RJ, Joniau S, et al. Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer. Urol Oncol 2016;34:234.e13\u20139.","DOI":"10.1016\/j.urolonc.2015.11.018"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818300216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818300216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T04:42:27Z","timestamp":1570682547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283818300216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0302283818300216"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2018.01.012","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2018.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}